Vinflunine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A chemotherapeutic agent used in cancer treatment}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Vinflunine.svg | |||
| image2 = <!-- Another image if available --> | |||
}} | |||
'''Vinflunine''' is a [[chemotherapeutic agent]] used in the treatment of various types of [[cancer]]. It is a [[vinca alkaloid]] derivative, specifically designed to improve upon the efficacy and safety profile of its predecessors, such as [[vincristine]] and [[vinblastine]]. | |||
Vinflunine | |||
== | ==Mechanism of Action== | ||
Vinflunine | Vinflunine works by inhibiting [[microtubule]] assembly, which is crucial for [[cell division]]. By disrupting the microtubule dynamics, vinflunine effectively halts the [[mitotic]] process, leading to [[apoptosis]] of the [[cancer cells]]. This mechanism is similar to other vinca alkaloids, but vinflunine has been modified to enhance its binding affinity and reduce [[neurotoxicity]]. | ||
== | ==Clinical Use== | ||
Vinflunine is primarily used in the treatment of [[urothelial carcinoma]], particularly in patients who have previously been treated with [[platinum-based chemotherapy]]. It has also been investigated for use in other types of cancer, including [[non-small cell lung cancer]] and [[breast cancer]]. | |||
== | ==Side Effects== | ||
Common side effects of vinflunine include [[neutropenia]], [[anemia]], [[constipation]], and [[fatigue]]. Less common but serious side effects can include [[cardiotoxicity]] and [[neurotoxicity]]. Patients undergoing treatment with vinflunine require regular monitoring of their [[blood cell counts]] and [[organ function]]. | |||
== | ==Pharmacokinetics== | ||
Vinflunine is administered intravenously and has a complex [[pharmacokinetic]] profile. It is extensively metabolized in the [[liver]], primarily by the [[cytochrome P450]] enzyme system. The drug and its metabolites are excreted mainly through the [[biliary]] route. | |||
==Development and Approval== | |||
Vinflunine was developed by [[Pierre Fabre]] Laboratories and received approval for use in the [[European Union]] in 2009. It is not approved by the [[Food and Drug Administration]] (FDA) for use in the [[United States]]. | |||
==Related pages== | |||
* [[Vinca alkaloid]] | * [[Vinca alkaloid]] | ||
* [[ | * [[Chemotherapy]] | ||
* [[ | * [[Cancer treatment]] | ||
[[Category: | [[Category:Chemotherapeutic agents]] | ||
[[Category:Vinca alkaloids]] | [[Category:Vinca alkaloids]] | ||
Revision as of 03:38, 13 February 2025
A chemotherapeutic agent used in cancer treatment
| Vinflunine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Vinflunine is a chemotherapeutic agent used in the treatment of various types of cancer. It is a vinca alkaloid derivative, specifically designed to improve upon the efficacy and safety profile of its predecessors, such as vincristine and vinblastine.
Mechanism of Action
Vinflunine works by inhibiting microtubule assembly, which is crucial for cell division. By disrupting the microtubule dynamics, vinflunine effectively halts the mitotic process, leading to apoptosis of the cancer cells. This mechanism is similar to other vinca alkaloids, but vinflunine has been modified to enhance its binding affinity and reduce neurotoxicity.
Clinical Use
Vinflunine is primarily used in the treatment of urothelial carcinoma, particularly in patients who have previously been treated with platinum-based chemotherapy. It has also been investigated for use in other types of cancer, including non-small cell lung cancer and breast cancer.
Side Effects
Common side effects of vinflunine include neutropenia, anemia, constipation, and fatigue. Less common but serious side effects can include cardiotoxicity and neurotoxicity. Patients undergoing treatment with vinflunine require regular monitoring of their blood cell counts and organ function.
Pharmacokinetics
Vinflunine is administered intravenously and has a complex pharmacokinetic profile. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system. The drug and its metabolites are excreted mainly through the biliary route.
Development and Approval
Vinflunine was developed by Pierre Fabre Laboratories and received approval for use in the European Union in 2009. It is not approved by the Food and Drug Administration (FDA) for use in the United States.
